dsip-safety-data DSIP DSIP Peptide for Detox |

These receptors are expressed in various tissues and cells, enabling VIP to exert its pleiotropic effects

About the Author Maryke Louw is a chartered physiotherapist with more than 20 years' experience and a Masters Degree in Sports Injury Management

10.1038/s41598-017-15028-x 106

Key gaps include: No large-scale randomised controlled trials in humans the evidence basis for clinical use is extrapolated from animal data and small pilot studies No long-term safety data effects beyond 1216 weeks are not well characterised Variable results in human sleep trials some early human studies showed modest or inconsistent effects on sleep architecture compared to animal data, suggesting the translation may not be linear No FDA approval DSIP is not approved for any therapeutic use in the United States Stability concerns DSIP degrades relatively quickly in circulation